Farry J P, Fischl S J, Tighe M J, Krell M J
Division of Cardiology, Overlook Hospital, Summit, New Jersey.
Am J Med. 1989 Jan 23;86(1B):41-4. doi: 10.1016/0002-9343(89)90128-9.
Twenty hypertensive patients entered a crossover, placebo-controlled study of prazosin and labetalol that was designed to compare treatment effects on blood pressure control and lipid parameters. Both drugs significantly reduced sitting and standing systolic and diastolic blood pressures (p less than or equal to 0.01). No significant differences were noted between treatment groups in total cholesterol, high-density lipoprotein cholesterol, or very low-density lipoprotein cholesterol levels. However, a trend toward an increase in low-density lipoprotein cholesterol levels was seen during therapy with labetalol, whereas in contrast, no such effect was seen during treatment with prazosin.
20名高血压患者进入了一项关于哌唑嗪和拉贝洛尔的交叉、安慰剂对照研究,该研究旨在比较两种药物对血压控制和血脂参数的治疗效果。两种药物均能显著降低坐位和立位的收缩压和舒张压(p≤0.01)。治疗组之间在总胆固醇、高密度脂蛋白胆固醇或极低密度脂蛋白胆固醇水平方面未观察到显著差异。然而,在使用拉贝洛尔治疗期间,低密度脂蛋白胆固醇水平有升高的趋势,而相比之下,使用哌唑嗪治疗期间未观察到此类影响。